Hypereosinophilic Syndrome Market: The benralizumab segment held a prominent market share

Retrieved on: 2022-02-02 06:51:24

Tags for this article:

Click the tags to see associated articles and topics

Hypereosinophilic Syndrome Market: The benralizumab segment held a prominent market share. View article details on hiswai:

Excerpt

Novel targeted therapies, including tyrosine kinase inhibitors and monoclonal antibodies, are some of the latest trends in the hypereosinophilic ...

Article found on: www.biospace.com